# Comparing plasma p-tau217 and plasma p-tau217/Aβ 42 with CSF biomarkers for assessing Alzheimer’s disease pathology

Source: [nature.com](https://www.nature.com/articles/s43587-026-01259-z) · 2026-11-18 · Medicine
Page: https://themorning.science/story/comparing-plasma-p-tau217-and-plasma-p-tau217-a-42-with-csf-biomarkers-for-asses-0566d8a67654c93b
Kind: research · Impact: medium

## In brief

- A Nature Aging study compares blood tests for p-tau217 and p-tau217/Aβ42 with CSF biomarkers for assessing Alzheimer's disease pathology.
- The source describes the blood tests, including regulatory-authorized ones, as accessible and cost-effective diagnostic tools.
- The source excerpt is cut off before the full results, but it states the blood tests perform similarly to the CSF biomarkers.

## Why it matters

If blood tests perform similarly to cerebrospinal fluid biomarkers, they could offer a less invasive and cheaper way to assess Alzheimer's pathology.

## Timeline

- 2026-11-18: Study published online in Nature Aging

## Coverage

- [Comparing plasma p-tau217 and plasma p-tau217/Aβ 42 with CSF biomarkers for assessing Alzheimer’s disease pathology](https://www.nature.com/articles/s43587-026-01259-z) — nature.com, 2026-11-18

Tags: alzheimer, biomarkers, blood test, p-tau217, diagnostics

---

Brief generated by AI (claude-haiku-5-5) from the reporting listed under Coverage. Headlines belong to their publishers. The Morning Science – https://themorning.science
